Statin improves flow-mediated vasodilation in chronic kidney diseases

International Journal of Hypertension

Volumn 2013, Issue , 2013, Pages

  Takenaka, Tsuneo ^a,b   Takane, Hiroshi ^b   Kikuta, Tomohiro ^b   Watanabe, Yusuke ^b   Suzuki, Hiromichi ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FLOW MEDIATED VASODILATION; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROTEINURIA; UPREGULATION; VASODILATATION;

EID: 84896703974     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2013/876865     Document Type: Article

References (37)

1. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003 108 17 2154 2169 2- (Pubitemid 37337595)
2. Lindner A., Charra B., Sherrard D. J., Scribner B. H., Accelerated atherosclerosis in prolonged maintenance hemodialysis. New England Journal of Medicine 1974 290 13 697 701 2-s2.0-0016403709
3. Higashi Y., Kihara Y., Noma K., Endothelial dysfunction and hypertension in aging. Hypertension Research 2012 35 11 1039 1047 10.1038/hr.2012.138
4. Ross R., Atherosclerosis-an inflammatory disease. New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
5. Locatelli F., Pozzoni P., Tentori F., del Vecchio L., Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003 18 supplement 7 vii2 vii9 10.1093/ndt/gfg1072 2-s2.0-0042885532 (Pubitemid 37098602)
6. Yilmaz M. I., Saglam M., Caglar K., Cakir E., Sonmez A., Ozgurtas T., Aydin A., Eyileten T., Ozcan O., Acikel C., Tasar M., Genctoy G., Erbil K., Vural A., Zoccali C., The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. American Journal of Kidney Diseases 2006 47 1 42 50 2-s2.0-29244461434 10.1053/j.ajkd.2005.09.029 (Pubitemid 41828265)
7. Kronenberg F., Dyslipidemia and nephrotic syndrome: recent advances. Journal of Renal Nutrition 2005 15 2 195 203 2-s2.0-17044410073 10.1053/j.jrn.2004.10.003
8. Chang T. I., Desai M., Solomon D. H., Winkelmayer W. C., Kidney function and long-term medication adherence after myocardial infarction in the elderly. Clinical Journal of the American Society of Nephrology 2011 6 4 864 869 2-s2.0-79955550907 10.2215/CJN.07290810
9. Japan Atherosclerosis Society, Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 2012 Kyorin Co. Ltd.
10. Yu M., Kim Y. J., Kang D. H., Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology 2011 6 1 30 39 2-s2.0-79251528072 10.2215/CJN.05340610
11. Krenning G., Dankers P. Y. W., Drouven J. W., Waanders F., Franssen C. F. M., Van Luyn M. J. A., Harmsen M. C., Popa E. R., Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. American Journal of Physiology-Renal Physiology 2009 296 6 F1314 F1322 2-s2.0-66449132290 10.1152/ajprenal.90755.2008
12. Vanhoutte P. M., How we learned to say NO. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 8 1156 1160 10.1161/ATVBAHA.109.190215
13. Brodsky S. V., Morrishow A. M., Dharia N., Gross S. S., Goligorsky M. S., Glucose scavenging of nitric oxide. American Journal of Physiology-Renal Physiology 2001 280 3 F480 F486 2-s2.0-0034980789
14. Mimura T., Takenaka T., Kanno Y., Moriwaki K., Okada H., Suzuki H., Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. Journal of Human Hypertension 2008 22 1 38 47 2-s2.0-37249066623 10.1038/sj.jhh.1002264 (Pubitemid 350269254)
15. Verhulst A., D'Haese P. C., De Broe M. E., Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. Journal of the American Society of Nephrology 2004 15 9 2249 2257 2-s2.0-4344566156 10.1097/01.ASN.0000136778.32499.05 (Pubitemid 39159325)
16. Takenaka T., Seto T., Okayama M., Kojima E., Nodaira Y., Sueyoshi K., Kikuta T., Watanabe Y., Inoue T., Takane H., Ohno Y., Suzuki H., Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study. American Journal of Nephrology 2012 35 5 416 423 2-s2.0-84859874167 10.1159/000338132
17. Kobayashi K., Ohno Y., Takenaka T., Ikeda N., Okada H., Kanno Y., Suzuki H., Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. Clinical and Experimental Hypertension 2011 33 2 100 105 2-s2.0-79960626427 10.3109/10641963.2010.531834
18. Japanese Society of Hypertension, Japanese Society of Nephrology, Guidelines for the Management of Chronic Kidney Diseases; Hypertension 2008 Tokyo-Igaku Co. Ltd.
19. Ogihara T., Nakao K., Fukui T., Fukiyama K., Ueshima K., Oba K., Sato T., Saruta T., Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008 51 2 393 398 2-s2.0-38549181561 10.1161/HYPERTENSIONAHA.107.098475 (Pubitemid 351159955)
20. Suzuki H., Kanno Y., Sugahara S., Ikeda N., Shoda J., Takenaka T., Inoue T., Araki R., Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. American Journal of Kidney Diseases 2008 52 3 501 506 2-s2.0-49749083154 10.1053/j.ajkd.2008.04.031
21. Colhoun H. M., Betteridge D. J., Durrington P. N., Hitman G. A., Neil H. A. W., Livingstone S. J., Charlton-Menys V., DeMicco D. A., Fuller J. H., Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases 2009 54 5 810 819 2-s2.0-70350121639 10.1053/j.ajkd.2009.03.022
22. Shepherd J., Kastelein J. J. P., Bittner V., Deedwania P., Breazna A., Dobson S., Wilson D. J., Zuckerman A., Wenger N. K., Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of the American Society of Nephrology 2007 2 6 1131 1139 2-s2.0-38449119409 10.2215/CJN.04371206
23. Baigent C., Landray M. J., Reith C., Emberson J., Wheeler D. C., Tomson C., Wanner C., Krane V., Cass A., Craig J., Neal B., Jiang L., Hooi L. S., Levin A., Agodoa L., Gaziano M., Kasiske B., Walker R., Massy Z. A., Feldt-Rasmussen B., Krairittichai U., Ophascharoensuk V., Fellström B., Holdaas H., Tesar V., Wiecek A., Grobbee D., De Zeeuw D., Grönhagen-Riska C., Dasgupta T., Lewis D., Herrington W., Mafham M., Majoni W., Wallendszus K., Grimm R., Pedersen T., Tobert J., Armitage J., Baxter A., Bray C., Chen Y., Chen Z., Hill M., Knott C., Parish S., Simpson D., Sleight P., Young A., Collins R., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 2011 377 9784 2181 2192 2-s2.0-79959746706 10.1016/S0140-6736(11)60739-3
24. Fellström B. C., Jardine A. G., Schmieder R. E., Holdaas H., Bannister K., Beutler J., Chae D. W., Chevaile A., Cobbe S. M., Grönhagen-Riska C., De Lima J. J., Lins R., Mayer G., McMahon A. W., Parving H. H., Remuzzi G., Samuelsson O., Sonkodi S., Süleymanlar G., Tsakiris D., Tesar V., Todorov V., Wiecek A., Wüthrich R. P., Gottlow M., Johnsson E., Zannad F., Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine 2009 360 14 1395 1407 2-s2.0-63849163945 10.1056/NEJMoa0810177
25. Takenaka T., Takahashi K., Kobayashi T., Oshima E., Iwasaki S., Suzuki H., Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clinical Nephrology 2002 58 1 33 37 2-s2.0-0036019837 (Pubitemid 34752991)
26. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Takeuchi M., Maeda S., Yamagishi S. I., Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxidative Medicine and Cellular Longevity 2010 3 5 304 307 2-s2.0-78650735024 10.4161/oxim.3.5.13069
27. Takemoto M., Okabe E., Kobayashi K., Fujimoto M., Kawamura Y., Ohnishi S., Ishikawa M., Ishibashi R., Yokote K., Renoprotective effects of atorvastatin om dyslipidemic patients with tyoe2 diabetes: influence on urinary podocyte Journal of the Japanese Diabetes Society 2012 55 supplement 1 S280
28. Mason R. P., Walter M. F., Day C. A., Jacob R. F., Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. American Journal of Cardiology 2005 96 supplement 5 11 23 2-s2.0-23944466455 10.1016/j.amjcard. 2005.06.008 (Pubitemid 41207729)
29. Siddiqi L., Joles J. A., Oey P. L., Blankestijn P. J., Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. Journal of Hypertension 2011 29 11 2176 2180 2-s2.0-80054106555 10.1097/HJH. 0b013e32834ae3c7
30. Mukerji N., Damodaran T. V., Winn M. P., TRPC6 and FSGS: the latest TRP channelopathy. Biochimica et Biophysica Acta 2007 1772 8 859 868 2-s2.0-34547438723 10.1016/j.bbadis.2007.03.005 (Pubitemid 47176375)
31. Takenaka T., Suzuki H., Okada H., Inoue T., Kanno Y., Ozawa Y., Hayashi K., Saruta T., Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Kidney International 2002 62 2 558 565 2-s2.0-0035991550 10.1046/j.1523-1755.2002.00484.x (Pubitemid 34779768)
32. Giunti S., Calkin A. C., Forbes J. M., Allen T. J., Thomas M. C., Cooper M. E., Jandeleit-Dahm K. A., The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. American Journal of Physiology-Renal Physiology 2010 299 3 F528 F535 2-s2.0-77956493744 10.1152/ajprenal.00127.2010
33. Zwaka T. P., Hombach V., Torzewski J., C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001 103 9 1194 1197 2-s2.0-0035814966 (Pubitemid 32221339)
34. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. Jr.M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
35. Schneider M. P., Schmidt B. M., John S., Schmieder R. E., Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. Journal of Hypertension 2011 29 9 1757 1764 2-s2.0-80051924459 10.1097/HJH.0b013e32834a509a
36. Ozaki K., Kubo T., Imaki R., Shinagawa H., Fukaya H., Ohtaki K., Ozaki S., Izumi T., Aizawa Y., The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 2006 13 4 216 219 2-s2.0-34250769307
37. Epstein M., Campese V. M., Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors on renal function. American Journal of Kidney Diseases 2005 45 1 2 14 2-s2.0-11144322775 10.1053/j.ajkd.2004.08.040 (Pubitemid 40038040)